Mouse CD20 expression and function.
暂无分享,去创建一个
Junji Uchida | Youngkyun Lee | K. Haas | J. Oliver | Youngkyun Lee | J. Uchida | T. Tedder | M. Hasegawa | D. Steeber | Douglas A Steeber | Yinghua Liang | A. Bradney | K. Bowen | J. Poe | Karen M Haas | Thomas F Tedder | Minoru Hasegawa | Yinghua Liang | Alice Bradney | Julie A Oliver | Kristina Bowen | Jonathan C Poe | Alice P. Bradney
[1] E. Génot,et al. Hyperphosphorylation of CD20 in hairy cells. Alteration by low molecular weight B cell growth factor and IFN-alpha. , 1991, Journal of immunology.
[2] T. Tedder,et al. Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. , 2001, Genomics.
[3] G. Pinkus,et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.
[4] B. Koller,et al. Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Neuberger,et al. Mice carrying a CD20 gene disruption , 1998, Immunogenetics.
[6] P. Sideras,et al. B Cell Development in the Spleen Takes Place in Discrete Steps and Is Determined by the Quality of B Cell Receptor–Derived Signals , 1999, The Journal of experimental medicine.
[7] R. Frizzell,et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes , 1993, The Journal of cell biology.
[8] M. Kanzaki,et al. Activation of a Calcium-permeable Cation Channel CD20 Expressed in Balb/c 3T3 Cells by Insulin-like Growth Factor-I* , 1997, The Journal of Biological Chemistry.
[9] I. Stamenkovic,et al. Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein , 1988, The Journal of experimental medicine.
[10] L. Nadler,et al. Expression of cell surface markers after human B lymphocyte activation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[11] T. Tedder,et al. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. , 1988, The Journal of biological chemistry.
[12] E. Clark,et al. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. , 1987, Journal of immunology.
[13] A. Freedman,et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. , 1985, Journal of immunology.
[14] J. Golay,et al. Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies. , 1987, Immunology.
[15] G. Kelsoe,et al. In Situ Studies of the Primary Immune Response to (4-Hydroxy-3-Nitrophenyl)Acetyl. V. Affinity Maturation Develops in Two Stages of Clonal Selection , 1998, The Journal of experimental medicine.
[16] E. Smeland,et al. The specific induction of myc protooncogene expression in normal human B cells is not a sufficient event for acquisition of competence to proliferate. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[17] G. Kelsoe,et al. In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations , 1991, The Journal of experimental medicine.
[18] A. Forsgren,et al. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes , 1986, European journal of immunology.
[19] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[20] M. Fujimoto,et al. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. , 1999, Immunity.
[21] M. Holder,et al. Engagement of CD20 suppresses apoptosis in germinal center B cells , 1995, European journal of immunology.
[22] B. Koller,et al. Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. , 1995, Immunity.
[23] P. Chu,et al. Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study , 2002, Leukemia & lymphoma.
[24] G. Schieven,et al. Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.
[25] J. Daley,et al. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development , 1994, Molecular and cellular biology.
[26] E. Clark,et al. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.
[27] G. Schieven,et al. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. , 1993, Journal of immunology.
[28] M. Kaminski,et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. , 1993, The New England journal of medicine.
[29] R. Al-Daccak,et al. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines , 1999, European journal of immunology.
[30] T. Tedder,et al. CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.
[31] K. Rajewsky,et al. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. , 1979, Journal of immunology.
[32] T. Tedder,et al. Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway. , 1991, Journal of immunology.
[33] T. Tedder,et al. Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). , 1989, Journal of immunology.
[34] M. Kanzaki,et al. Expression of Calcium-permeable Cation Channel CD20 Accelerates Progression through the G1 Phase in Balb/c 3T3 Cells(*) , 1995, The Journal of Biological Chemistry.
[35] D. Maloney,et al. Clinical status and optimal use of rituximab for B-cell lymphomas. , 1998, Oncology.
[36] I Royston,et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.
[37] E. Clark,et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. , 1989, The Journal of biological chemistry.
[38] M. Kaminski,et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Kanzaki,et al. Activation of the Calcium-permeable Cation Channel CD20 by α Subunits of the Gi Protein* , 1997, The Journal of Biological Chemistry.
[40] L. Nadler,et al. Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.
[41] S. Levy,et al. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.
[42] E. Génot,et al. Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. Evidence for involvement of calcium/calmodulin-dependent protein kinase II. , 1993, Journal of immunology.
[43] M. Introna,et al. Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. , 1992, Journal of immunology.
[44] J. Ledbetter,et al. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.
[45] G. Adams,et al. Monoclonal antibody therapy for cancer. , 2003, Annual review of medicine.
[46] M. Fujimoto,et al. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. , 1999, Journal of immunology.
[47] H. Saito,et al. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[48] G. Köhler,et al. Transitional B cells are the target of negative selection in the B cell compartment , 1995, The Journal of experimental medicine.
[49] D. Morris,et al. Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. , 1991, Journal of immunology.
[50] T. Tedder,et al. Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. , 1988, Molecular immunology.
[51] J. Brown,et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.
[52] S. A. Bush,et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Eary. Radioimmunotherapy of B-cell lymphoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] E. Clark,et al. Expression of the human B-cell surface protein CD20: alteration by phorbol 12-myristate 13-acetate. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[55] D. Adler,et al. Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. , 1988, Journal of immunology.